Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12863821 | 0.79 | CYP19A1 (0.40) | CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL30461849 | 0.77 | — | — | |
| SCHEMBL21558234 | 0.77 | POLB (0.37) | POLBKCNH2DYRK1A | |
| SCHEMBL25212373 | 0.77 | POLB (0.37) | POLBKCNH2DYRK1A | |
| SCHEMBL18250234 | 0.77 | POLB (0.37) | CYP11B1CYP11B2POLBKCNH2DYRK1A | |
| SCHEMBL13253965 | 0.75 | POLB (0.36) | POLBKCNH2DYRK1A | |
| SCHEMBL14417085 | 0.75 | POLB (0.33) | POLBKCNH2DYRK1A | |
| SCHEMBL2308094 | 0.75 | — | — | |
| SCHEMBL5654439 | 0.74 | CYP11B1 (0.44) | CYP11B1CYP11B2POLBKCNH2DYRK1A | |
| SCHEMBL13059068 | 0.74 | POLB (0.35) | CYP11B1CYP11B2POLBKCNH2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742168-B2 | Process for the production of acetic acid | LYONDELL CHEMICAL TECHNOLOGY, L.P. (US) | 2014-06-03 | — | — | US | claimed |
| US-8637699-B2 | Process for the manufacture of acetic acid | LYONDELL CHEMICAL TECHNOLOGY, L.P. (US) | 2014-01-28 | — | — | US | claimed |
| US-20120310009-A1 | Process for the Production of Acetic Acid | LYONDELL CHEMICAL COMPANY (US) | 2012-12-06 | — | — | US | claimed |
| US-20120264971-A1 | PROCESS FOR THE MANUFACTURE OF ACETIC ACID | LYONDELLBASELL ACETYLS, LLC | 2012-10-18 | — | — | US | claimed |
| US-11155523-B2 | Biphenyl compound as CCR2/CCR5 receptor antagonist | MEDSHINE DISCOVERY, INC. (CN) | 2021-10-26 | — | — | US | disclosed |
| US-20200223801-A1 | Biphenyl Compound As CCR2/CCR5 Receptor Antagonist | MEDSHINE DISCOVERY, INC. (CN) | 2020-07-16 | — | — | US | disclosed |
| US-10611732-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-07 | — | — | US | disclosed |
| US-20190322628-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-24 | — | — | US | disclosed |
| US-10370340-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-06 | — | — | US | disclosed |
| US-9981919-B2 | HIV replication inhibiting pyrimidines | JANSSEN PHARMACEUTICAL N.V. (BE) | 2018-05-29 | — | — | US | disclosed |
| US-20170320835-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-09 | — | — | US | disclosed |
| US-20170121292-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-04 | — | — | US | disclosed |
| US-20120310009-A1 | Process for the Production of Acetic Acid | LYONDELL CHEMICAL COMPANY (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120264971-A1 | PROCESS FOR THE MANUFACTURE OF ACETIC ACID | LYONDELLBASELL ACETYLS, LLC | 2012-10-18 | — | — | US | disclosed |
| US-20120076835-A1 | HIV INHIBITING PYRIMIDINES DERIVATIVES | GUILLEMONT JEROME EMILE GEORGES (FR) | 2012-03-29 | — | — | US | disclosed |
| US-20120076835-A1 | HIV INHIBITING PYRIMIDINES DERIVATIVES | GUILLEMONT JEROME EMILE GEORGES (FR) | 2012-03-29 | — | — | US | disclosed |
| US-8080551-B2 | HIV inhibiting pyrimidines derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-20 | — | — | US | disclosed |
| US-20100034810-A1 | PYRIMIDINE DERIVATIVES FOR THE PREVENTION OF HIV INFECTION | JANSSEN-CILAG (FR) | 2010-02-11 | — | — | US | disclosed |
| US-20070021449-A1 | Pyrimidine derivatives for the prevention of hiv infection | HEERES JAN | 2007-01-25 | — | — | US | disclosed |
| US-20070021449-A1 | Pyrimidine derivatives for the prevention of hiv infection | HEERES JAN | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121292-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | RRM2B, CCNO, RRM2 | CYP19A1 2049/4885CYP11B1 715/4885CYP11B2 1015/4885 |
| US-20070021449-A1 | Pyrimidine derivatives for the prevention of hiv infection | ADORA2B, CYP1B1, DPYD | CYP19A1 139/4885CYP11B1 360/4885CYP11B2 537/4885 |
| US-20120264971-A1 | PROCESS FOR THE MANUFACTURE OF ACETIC ACID | DBI, IDH1, ACAD9 | CYP19A1 747/4885CYP11B1 12/4885CYP11B2 20/4885 |
| US-11155523-B2 | Biphenyl compound as CCR2/CCR5 receptor antagonist | CCR2, CCR5, CCRL2 | CYP19A1 964/4885CYP11B1 158/4885CYP11B2 101/4885 |
| US-20190322628-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | RRM2B, CCNO, RRM2 | CYP19A1 2049/4885CYP11B1 715/4885CYP11B2 1015/4885 |
| US-20200223801-A1 | Biphenyl Compound As CCR2/CCR5 Receptor Antagonist | CCR2, CCR5, CCRL2 | CYP19A1 964/4885CYP11B1 158/4885CYP11B2 101/4885 |
| US-10611732-B2 | HIV replication inhibiting pyrimidines | RRM2B, CCNO, RRM2 | CYP19A1 2049/4885CYP11B1 715/4885CYP11B2 1015/4885 |
| US-20120076835-A1 | HIV INHIBITING PYRIMIDINES DERIVATIVES | TYMS, PNP, DUT | CYP19A1 1817/4885CYP11B1 716/4885CYP11B2 893/4885 |
| US-20120310009-A1 | Process for the Production of Acetic Acid | DBI, FLI1, ACADM | CYP19A1 739/4885CYP11B1 13/4885CYP11B2 17/4885 |
| US-20100034810-A1 | PYRIMIDINE DERIVATIVES FOR THE PREVENTION OF HIV INFECTION | NOX3, CBR3, CBR1 | CYP19A1 129/4885CYP11B1 116/4885CYP11B2 163/4885 |
| US-10370340-B2 | HIV replication inhibiting pyrimidines | RRM2B, CCNO, RRM2 | CYP19A1 2049/4885CYP11B1 715/4885CYP11B2 1015/4885 |
| US-20170320835-A1 | HIV REPLICATION INHIBITING PYRIMIDINES | RRM2B, CCNO, RRM2 | CYP19A1 2049/4885CYP11B1 715/4885CYP11B2 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.